The National Institute of Health (NIH) reinstated a $7.5 million grant to the nonprofit research organization EcoHealth Alliance.
The National Institutes of Health (NIH) launched a study to evaluate drugs prescribed to treat COVID-19, the respiratory disease caused by the new coronavirus, among children and adolescents across the United States.
The best-known genetic marker for Alzheimer’s disease is ApoE4 – a form of apolipoprotein E – which is a protein involved in repairing neurons injured by aging, stroke or other reasons.
As Chinese Coronavirus Spreads, Biopharma and Governments Rush to Develop Vaccines
Australia, Canada, China, Coronavirus, Coronavirus Vaccines, Ebola, France, Japan, Malaysia, Messenger RNA (mRNA) Vaccines, National Health Commission (China), National Institute of Health, Outbreaks, South Korea, Thailand, Trump Administration, United States, Vietnam, World Health Organization, WuhanChina’s National Health Commission stated today that the coronavirus has infected 5,974 individuals, resulting in 132 deaths and 103 people being cured.
The advent of increasingly more mainstream and affordable genetic testing enables powerful genetic research – but that power is directly associated with the strength and diversity of the database of genetic information available.
VistaGen’s Antidepressant Fails in Difficult-to-Treat Patients Trial
Antidepressants, Clinical Trials, CNS, Fast Track Designation, FDA, Major Depressive Disorder (MDD), N-methyl-D-aspartate (NMDA) receptor, Nasal Sprays, National Institute of Health, Social Anxiety Disorder, Treatment-Resistant DepressionWhen major depressive disorder does not respond to at least two different types of antidepressant treatments in a moderate-to-severe depressive episode, it’s reclassified as treatment-resistant depression (TRD). South San Francisco-based VistaGen Therapeutics’ AV-101 failed to meet the primary efficacy endpoints for TRD in a Phase II clinical trial.
Companies Continue to Take Aim at Glioblastoma, a Cancer Highlighted by the Death of Sen. John McCain
Antigens, Brain Cancer, China Food and Drug Administration, Clinical Trials, Clinical Trials, Gene Therapy, Glioblastoma Multiforme (GBM), Immunotherapies, National Institute of Health, Proteasome Inhibitors, R&D, Rare Diseases, Small MoleculesCiting the National Institutes of Health (NIH), CNN reported there are 274 glioblastoma multiforme studies underway or recruiting across the United States.
The National Institutes of Health said it had partnered 11 biopharma companies to help advance a new class of drugs that uses the body’s immune system to fight cancer.
President Donald Trump’s 2018 budget proposal takes a machete to the spending plans of nationally funded health programs that fund medical research, disease prevention and insurance plans.
Heron Therapeutics Inc.’s twice-rejected long-acting injection to prevent chemotherapy-induced nausea and vomiting was finally approved by the U.S. FDA.